<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01270880</url>
  </required_header>
  <id_info>
    <org_study_id>2010-070</org_study_id>
    <secondary_id>NCI-2010-02328</secondary_id>
    <nct_id>NCT01270880</nct_id>
  </id_info>
  <brief_title>Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy</brief_title>
  <official_title>A Phase II Trial of STA-9090 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins&#xD;
      needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090&#xD;
      works in treating patients with metastatic hormone-resistant prostate cancer previously&#xD;
      treated with docetaxel-based chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate progression-free survival (PFS) achieved with STA-9090 (Hsp90 inhibitor&#xD;
      STA-9090) in men with castration-resistant prostate cancer (CRPC) who have received prior&#xD;
      docetaxel based therapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the percentage change in prostate-specific antigen (PSA) from baseline to 12&#xD;
      weeks.&#xD;
&#xD;
      II. To assess overall safety and tolerability of STA-9090. III. To evaluate overall survival&#xD;
      (OS) outcome in metastatic CRPC who have received prior docetaxel therapy.&#xD;
&#xD;
      IV. To investigate the association of progression-free survival (PFS) and PSA response rate&#xD;
      with primary and secondary target markers.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate potential markers for predicting drug response or efficacy, blood samples will&#xD;
      be used to collect the serum and extract messenger ribonucleic acid (mRNA) from mononuclear&#xD;
      cells and analyzed by quantitative real-time polymerase chain reaction (PCR) and/or&#xD;
      enzyme-linked immunosorbent assay (ELISA).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive Hsp90 inhibitor STA-9090 intravenously (IV) over 1 hour once weekly in weeks&#xD;
      1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy</measure>
    <time_frame>At 6 months</time_frame>
    <description>Our primary objective was to determine the 6-month PFS rate by using a binary (yes/no) endpoint of 6 months of PFS. Treatment success was defined as achievement of at least 6 months of PFS. Patients who did not complete 6 months of ganetespib therapy for any reason (including death from any cause) were considered treatment failures and were recorded as not achieving the primary endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in PSA</measure>
    <time_frame>From baseline to 12 weeks</time_frame>
    <description>Percentage change in PSA from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Safety and Tolerability of STA-9090</measure>
    <time_frame>Day 1, 8, and 15 of each course and at end of treatment</time_frame>
    <description>Overall safety and tolerability of STA-9090 by total number of grade 3 adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in Metastatic CRPC Who Have Received Prior Docetaxel Therapy</measure>
    <time_frame>From first dose to death or the date last known alive</time_frame>
    <description>Overall Survival (OS) in metastatic Castrate Resistant Prostate Cancer (CRPC) who have received prior docetaxel therapy using Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of PFS With PSA</measure>
    <time_frame>At 6 months</time_frame>
    <description>Association of PFS with PSA using Cox PH regression model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential Markers for Predicting Drug Response or Efficacy</measure>
    <time_frame>At baseline, day 1 of course 3, and end of treatment</time_frame>
    <description>Potential markers for predicting drug response or efficacy : This is not a measurable outcome, but a possible entity for further study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Hormone-resistant Prostate Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hsp90 inhibitor STA-9090</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>STA-9090</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>enzyme-linked immunosorbent assay</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>ELISA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>spectrophotometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
    <other_name>RT-PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzyme inhibitor therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed diagnosis of prostate adenocarcinoma with metastasis and&#xD;
             objective progression or rising PSA despite androgen deprivation therapy and&#xD;
             antiandrogen withdrawal when applicable&#xD;
&#xD;
          -  Progression after docetaxel based chemotherapy is needed as follows:&#xD;
&#xD;
          -  a) If measurable disease present, then either rising PSA, increase in size of the&#xD;
             lesion/s or both should be present&#xD;
&#xD;
          -  b) Patients with rising PSA only as progression must demonstrate a rising trend with 2&#xD;
             successive elevations at minimum intervals of 1 week; a minimum PSA of 5 ng/ml, or new&#xD;
             areas of bony metastases on bone scan are required for patients with no measurable&#xD;
             disease; no minimum PSA requirement for patients with measurable disease&#xD;
&#xD;
          -  Patients should have received at least one prior docetaxel based regimen for&#xD;
             metastatic disease; no maximum prior therapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Prior radiation therapy or chemotherapy completed at least 28 days prior to enrollment&#xD;
&#xD;
          -  All patients must be documented to be castrate with a testosterone level =&lt; 0.5 ng/ml;&#xD;
             luteinizing-hormone-releasing hormone (LHRH) agonist therapy must be continued, if&#xD;
             required to maintain castrate levels of testosterone; patients must be off&#xD;
             antiandrogens for a minimum of 4 weeks for flutamide and 6 weeks for bicalutamide or&#xD;
             nilutamide&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500 cells/uL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/uL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x upper limit of normal (ULN); Note: if serum creatinine is &gt;&#xD;
             1.5 x ULN, subject is eligible if the calculated creatinine clearance (CLcr) is &gt;= 50&#xD;
             mL/min&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN&#xD;
&#xD;
          -  For patients without documented bone metastases or for patients with liver metastases:&#xD;
             transaminases (aspartate aminotransferase [AST]/serum glutamic oxaloacetic&#xD;
             transaminase [SGOT] and/or alanine aminotransferase (ALT)/serum glutamic pyruvic&#xD;
             transaminase [SGPT]) may be up to 2.5 x institutional ULN if alkaline phosphatase is&#xD;
             =&lt; ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are =&lt; ULN&#xD;
&#xD;
          -  For patients with documented bone metastases, the transaminases (AST/SGOT and/or&#xD;
             ALT/SGPT) should be less than 2.5 x institutional ULN, without regard to the alkaline&#xD;
             phosphatase level&#xD;
&#xD;
          -  Sexually active males must use measures to prevent pregnancy in their partners while&#xD;
             on STA-9090&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to first dose of STA-9090&#xD;
&#xD;
          -  Poor venous access for study drug administration or would require a peripheral or&#xD;
             central indwelling catheter for study drug administration; study drug administration&#xD;
             via indwelling catheters is prohibited at this time&#xD;
&#xD;
          -  Use of any chemotherapy or other standard systemic treatments for prostate cancer,&#xD;
             including investigational agents within 2 weeks or 6 half- lives of the agent,&#xD;
             whichever is shorter, prior to receiving STA-9090; there must be at least 2 weeks&#xD;
             between the end of palliative radiation and the start of study drug and all radiation&#xD;
             therapy (XRT)-associated toxicities resolved to Grade 1 or 0&#xD;
&#xD;
          -  History of severe allergic or hypersensitivity reactions to excipients (e.g.,&#xD;
             Polyethylene glycol [PEG] 300 and Polysorbate 80 [i.e. docetaxel])&#xD;
&#xD;
          -  Baseline QTc &gt; 450 msec or previous history of QT prolongation while taking other&#xD;
             medications&#xD;
&#xD;
          -  Ventricular ejection fraction (Ef) =&lt; 55% at baseline&#xD;
&#xD;
          -  Any history of current coronary artery disease, myocardial infarction, angina&#xD;
             pectoris, angioplasty or coronary bypass surgery&#xD;
&#xD;
          -  History of current uncontrolled dysrhythmias, or requirement for antiarrhythmic&#xD;
             medications, or Grade 2 or greater left bundle branch block&#xD;
&#xD;
          -  New York Heart Association class II/III/IV congestive heart failure with a history of&#xD;
             dyspnea, orthopnea, or edema that requires current treatment with angiotensin&#xD;
             converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers or&#xD;
             diuretics&#xD;
&#xD;
          -  Current or prior radiation therapy to the left hemithorax&#xD;
&#xD;
          -  Treatment with chronic immunosuppressants (e.g. cyclosporine following&#xD;
             transplantation)&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, human&#xD;
             immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral&#xD;
             therapy, ongoing or active infection, symptomatic congestive heart failure, unstable&#xD;
             angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          -  Other medications, or severe acute/chronic medical or psychiatric condition, or&#xD;
             laboratory abnormality that may increase the risk associated with study participation&#xD;
             or study drug administration, or may interfere with the interpretation of study&#xD;
             results, and in the judgment of the investigator would make the subject inappropriate&#xD;
             for entry into this study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Heath</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine nd Denistry of New Jersey</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Cancer Center Riverview</name>
      <address>
        <city>Wisconsin Rapids</city>
        <state>Wisconsin</state>
        <zip>54494</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2011</study_first_posted>
  <results_first_submitted>April 1, 2015</results_first_submitted>
  <results_first_submitted_qc>April 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 14, 2015</results_first_posted>
  <last_update_submitted>August 19, 2018</last_update_submitted>
  <last_update_submitted_qc>August 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Elisabeth Heath</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Hsp90 inhibitor STA-9090: Given IV&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
enzyme-linked immunosorbent assay: Correlative studies&#xD;
RNA analysis: Correlative studies&#xD;
spectrophotometry: Correlative studies&#xD;
reverse transcriptase-polymerase chain reaction: Correlative studies&#xD;
gene expression analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Never rec'd treatment, but registered.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Hsp90 inhibitor STA-9090: Given IV&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
enzyme-linked immunosorbent assay: Correlative studies&#xD;
RNA analysis: Correlative studies&#xD;
spectrophotometry: Correlative studies&#xD;
reverse transcriptase-polymerase chain reaction: Correlative studies&#xD;
gene expression analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="51" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy</title>
        <description>Our primary objective was to determine the 6-month PFS rate by using a binary (yes/no) endpoint of 6 months of PFS. Treatment success was defined as achievement of at least 6 months of PFS. Patients who did not complete 6 months of ganetespib therapy for any reason (including death from any cause) were considered treatment failures and were recorded as not achieving the primary endpoint.</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Hsp90 inhibitor STA-9090: Given IV&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
enzyme-linked immunosorbent assay: Correlative studies&#xD;
RNA analysis: Correlative studies&#xD;
spectrophotometry: Correlative studies&#xD;
reverse transcriptase-polymerase chain reaction: Correlative studies&#xD;
gene expression analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy</title>
          <description>Our primary objective was to determine the 6-month PFS rate by using a binary (yes/no) endpoint of 6 months of PFS. Treatment success was defined as achievement of at least 6 months of PFS. Patients who did not complete 6 months of ganetespib therapy for any reason (including death from any cause) were considered treatment failures and were recorded as not achieving the primary endpoint.</description>
          <units>proportion with 6+ months PFS</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in PSA</title>
        <description>Percentage change in PSA from baseline.</description>
        <time_frame>From baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Hsp90 inhibitor STA-9090: Given IV&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
enzyme-linked immunosorbent assay: Correlative studies&#xD;
RNA analysis: Correlative studies&#xD;
spectrophotometry: Correlative studies&#xD;
reverse transcriptase-polymerase chain reaction: Correlative studies&#xD;
gene expression analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in PSA</title>
          <description>Percentage change in PSA from baseline.</description>
          <units>percentage change from baseline PSA</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.65" lower_limit="34.11" upper_limit="353.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Safety and Tolerability of STA-9090</title>
        <description>Overall safety and tolerability of STA-9090 by total number of grade 3 adverse events</description>
        <time_frame>Day 1, 8, and 15 of each course and at end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Hsp90 inhibitor STA-9090: Given IV&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
enzyme-linked immunosorbent assay: Correlative studies&#xD;
RNA analysis: Correlative studies&#xD;
spectrophotometry: Correlative studies&#xD;
reverse transcriptase-polymerase chain reaction: Correlative studies&#xD;
gene expression analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Safety and Tolerability of STA-9090</title>
          <description>Overall safety and tolerability of STA-9090 by total number of grade 3 adverse events</description>
          <units>events of grade 3+ toxicity</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in Metastatic CRPC Who Have Received Prior Docetaxel Therapy</title>
        <description>Overall Survival (OS) in metastatic Castrate Resistant Prostate Cancer (CRPC) who have received prior docetaxel therapy using Kaplan-Meier method</description>
        <time_frame>From first dose to death or the date last known alive</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Hsp90 inhibitor STA-9090: Given IV&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
enzyme-linked immunosorbent assay: Correlative studies&#xD;
RNA analysis: Correlative studies&#xD;
spectrophotometry: Correlative studies&#xD;
reverse transcriptase-polymerase chain reaction: Correlative studies&#xD;
gene expression analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>OS in Metastatic CRPC Who Have Received Prior Docetaxel Therapy</title>
          <description>Overall Survival (OS) in metastatic Castrate Resistant Prostate Cancer (CRPC) who have received prior docetaxel therapy using Kaplan-Meier method</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="1.5" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of PFS With PSA</title>
        <description>Association of PFS with PSA using Cox PH regression model</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Hsp90 inhibitor STA-9090: Given IV&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
enzyme-linked immunosorbent assay: Correlative studies&#xD;
RNA analysis: Correlative studies&#xD;
spectrophotometry: Correlative studies&#xD;
reverse transcriptase-polymerase chain reaction: Correlative studies&#xD;
gene expression analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Association of PFS With PSA</title>
          <description>Association of PFS with PSA using Cox PH regression model</description>
          <units>Hazard Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.999" upper_limit="1.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potential Markers for Predicting Drug Response or Efficacy</title>
        <description>Potential markers for predicting drug response or efficacy : This is not a measurable outcome, but a possible entity for further study.</description>
        <time_frame>At baseline, day 1 of course 3, and end of treatment</time_frame>
        <population>No data was collected for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Enzyme Inhibitor Therapy)</title>
            <description>Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Hsp90 inhibitor STA-9090: Given IV&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
enzyme-linked immunosorbent assay: Correlative studies&#xD;
RNA analysis: Correlative studies&#xD;
spectrophotometry: Correlative studies&#xD;
reverse transcriptase-polymerase chain reaction: Correlative studies&#xD;
gene expression analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Potential Markers for Predicting Drug Response or Efficacy</title>
          <description>Potential markers for predicting drug response or efficacy : This is not a measurable outcome, but a possible entity for further study.</description>
          <population>No data was collected for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Enzyme Inhibitor Therapy)</title>
          <description>Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Hsp90 inhibitor STA-9090: Given IV&#xD;
laboratory biomarker analysis: Correlative studies&#xD;
polymerase chain reaction: Correlative studies&#xD;
enzyme-linked immunosorbent assay: Correlative studies&#xD;
RNA analysis: Correlative studies&#xD;
spectrophotometry: Correlative studies&#xD;
reverse transcriptase-polymerase chain reaction: Correlative studies&#xD;
gene expression analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Investigations, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increase</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Investigations - other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elisabeth I. Heath, M.D.</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>313-576-8715</phone>
      <email>heathe@karmanos.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

